Trials / Completed
CompletedNCT02703051
A Study to Evaluate the PK, Safety and Tolerability of GMI-1271 With and Without Filgrastim in Healthy Adult Subjects
A Phase 1, Open-Label Study to Evaluate the Pharmacodynamics, Safety and Tolerability of GMI-1271 With and Without Filgrastim in Healthy Adult Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 54 (actual)
- Sponsor
- GlycoMimetics Incorporated · Industry
- Sex
- All
- Age
- 19 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
Phase 1, open-label, parallel, active-controlled, multiple IV dose, proof of concept study conducted at one study center in the United States (US).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GMI-1271 | |
| DRUG | Filgrastim | |
| DRUG | Placebo Injection | |
| DRUG | Placebo Infusion |
Timeline
- Start date
- 2015-11-01
- Primary completion
- 2016-08-01
- Completion
- 2016-08-01
- First posted
- 2016-03-09
- Last updated
- 2018-02-27
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02703051. Inclusion in this directory is not an endorsement.